Clinical Trials Browser

Phase 2 × onvansertib × Thoracic × Clear all

NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma